BioAgilytix names Euan Menzies CEO, adds former Labcorp CEO David King to board after $2.5B deal


A Durham company with hundreds of employees has a new CEO in the wake of a buyout that values the firm at $2.5 billion.

Previous This Boston medtech founder moved to St. Pete a year ago. With a new exit, now he's focusing on local commitment.
Next Chain of medical practices specializing in senior care coming to Triad